SPRY Stock Summary and Trading Ideas (Ars Pharmaceuticals | NASDAQ:SPRY)

ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.

Ars Pharmaceuticals trades on the NASDAQ stock market under the symbol SPRY.

As of September 4, 2026, SPRY stock price declined to $5.62 with 799,457 million shares trading.

SPRY has a market cap of $558.89 million. This is considered a Small Cap stock.

Last quarter Ars Pharmaceuticals reported $34 million in Revenue and -$.63 earnings per share. This beat revenue expectation by $2 million and missed earnings estimates by -$.13.

In the last 3 years, SPRY traded as high as $18.90 and as low as $2.55.

The top ETF exchange traded funds that SPRY belongs to (by Net Assets): XBI, VTI, VXF, IWO, VTWO.

SPRY has underperformed the market in the last year with a return of -48.3%, while the SPY ETF gained +19.8%. In the last 3 month period, SPRY fell short of the market, returning -35.8%, while SPY returned +2.0%. However, in the most recent 2 weeks SPRY has outperformed the stock market by returning +2.1%, while SPY returned +0.6%.

SPRY support price is $5.39 and resistance is $5.95 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SPRY shares will trade within this expected range on the day.